Summary
Capybara Research presents a detailed investigative report exposing Safety Shot Inc, a company claiming to produce a revolutionary alcohol detox drink. The report reveals the drink's fraudulent claims and questionable management, urging caution to investors.
Who is Safety Shot Inc
Safety Shot Inc is a publicly traded company on the NASDAQ (ticker: SHOT) that markets a nutraceutical drink claiming to lower blood alcohol content (BAC) by up to 50% in 30 minutes. Founded through a complex history involving CBD products and acquisitions, Safety Shot now focuses primarily on this detox drink which has yet to be released. The company's management includes individuals with controversial backgrounds linked to disreputable practices and financial difficulties.
Key Points from Report
False Product Claims
- Safety Shot claims their drink can reduce BAC by up to 50% in 30 minutes, a claim refuted by medical science that states only time lowers BAC.
- The product allegedly prevents alcohol absorption by lining the stomach, though 80% of alcohol absorption occurs in the small intestine.
- Claims that the drink accelerates conversion of alcohol into sugar are inaccurate; alcohol metabolizes in the liver without converting to sugar.
Management and Background Concerns
- CEO Brian John and key executives previously worked at the infamous Stratton Oakmont, known for pump-and-dump schemes.
- Several leaders, including Miklos Gulyas and Jarrett Boon, have been involved in lawsuits, financial delinquencies, and allegedly deceptive business practices.
- Management faced legal disputes and financial troubles, including evictions, unpaid debts, and bankruptcies.
Stock Promotion and Financial Risks
- Safety Shot engages in aggressive stock promotion through third parties like SecretAlerts.com, SNN Inc (Planet MicroCap), and Nasdaq Picks to attract investors.
- The company has a history of dilution with convertible notes, warrants, and offerings increasing share count and potentially diluting shareholder value.
- Connections to firms with poor reputations, including Vinco Ventures (BBIG) and others facing delisting and lawsuits, raise concerns about business strategy.
Activ8 Finance Analysis
The report by Capybara Research highlights serious concerns regarding Safety Shot Inc's business practices, management integrity, and product legitimacy. Investors should be mindful of the numerous red flags including scientifically unfounded product claims, the backgrounds of the leadership team with histories of financial and legal troubles, and aggressive promotional activities that may inflate stock prices artificially. The ongoing dilution further complicates the company's financial outlook. Such factors collectively suggest caution when evaluating the company’s potential and underscore the importance of thorough due diligence.